A study published in Nature today has identified silent ancient DNA elements buried in our genome that when reactivated can initiate viral mimicry. Importantly, the team from the University of Toronto also discovered a key enzyme used by cancer cells to prevent this from happening in order to survive.
The enzyme is known as ADAR1, and it acts to prevent the cancer cells from signaling to the immune system. The scientists found that by inhibiting this enzyme, cancer cells were more sensitive to new drug therapies that induce viral mimicry.
"Humans acquired a series of silent repetitive elements in our DNA over millions of years of evolution, but it has been unclear why or what purpose they serve," explains lead researcher Daniel De Carvalho. "As 'genome archeologists', we set out to identify the function of these 'DNA relics' and have found that under the right conditions they can be reactivated and stimulate our immune system. These findings open up a new field of cancer therapies," says De Carvalho. "It gives us the opportunity to take advantage of these ancient repetitive DNA elements to fight cancer."
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
In their studies, epigenetic drugs were shown to reactivate these repetitive DNA elements and lead to the production of double-stranded RNA, a molecular pattern that is also observed following viral infection. This viral mimicry leads to an antiviral response directed specifically against cancer cells. In this latest research, they identified the specific ancient repetitive DNA elements as SINEs (Short Interspersed Nuclear Elements). These SINEs usually lie quietly in our genome, having little effect on the host. However, if activated by new epigenetic drugs, these SINES produce double-stranded RNA and can ultimately be used by cells to trigger an innate immune response.
"Since the ADAR1 activity is enzymatic, our work provides an exciting new target for drug development efforts for a completely new class of drugs that are able to exploit these 'ancient weapons' in our genome," De Carvalho concludes.